John Gerecitano
Head of Oncology Research & Development Sana Biotechnology
Seminars
Wednesday 9th September 2026
Scientific, Operational & Economic Realities for Immune-Modulating Therapies: What Have we Learnt so Far?
11:40 am
- Pharma’s reflections on recent in vivo CAR-T deals, what data was valuable when clinical data was minimal?
- Overlapping and diverging advantages of TCEs to in vivo CAR-T, including depth and durability of response.
- Debating clinical-adjacent innovations in delivery across viral vectors and LNPs and their application in immunology versus oncology
